title: Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report.
abstract: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1 - an aberrant tyrosine kinase - in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs.
authors.affiliation: Department of Experimental Oncology European Institute of Oncology, Milan, Italy.
authors.forename: Alicja M
authors.initials: AM
authors.lastname: Gruszka
authors.affiliation: Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Rabascio
authors.affiliation: Division of Hemato-oncology European Institute of Oncology, Milan, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Cannella
authors.affiliation: Division of Hemato-oncology European Institute of Oncology, Milan, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Sammassimo
authors.affiliation: Division of Hemato-oncology European Institute of Oncology, Milan, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Andreola
authors.affiliation: Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
authors.forename: Giuliana
authors.initials: G
authors.lastname: Gregato
authors.affiliation: Department of Experimental Oncology European Institute of Oncology, Milan, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Faretta
authors.affiliation: Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
authors.forename: Angelica
authors.initials: A
authors.lastname: Calleri
authors.affiliation: Department of Experimental Oncology European Institute of Oncology, Milan, Italy.
authors.forename: Rita
authors.initials: R
authors.lastname: De Molfetta
authors.affiliation: Division of Pathology, European Institute of Oncology, Milan, Italy.|Universita' degli Studi di Milano, Milan, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Pruneri
authors.affiliation: Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertolini
authors.affiliation: Department of Experimental Oncology European Institute of Oncology, Milan, Italy.|Universita' degli Studi di Milano, Milan, Italy.
authors.forename: Myriam
authors.initials: M
authors.lastname: Alcalay
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000097:blood / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D016411:Lymphoma, T-Cell, Peripheral / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl